Page last updated: 2024-08-26

peptide elongation factor 2 and nelfinavir

peptide elongation factor 2 has been researched along with nelfinavir in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
De Gassart, A; Demaria, O; Gilliet, M; Martinon, F; Panes, R; Ryazanov, AG; Zaffalon, L1
Campbell, ZT; Kunder, N; Loerch, S; Lou, TF; Smith, PR; Stanowick, AD1

Other Studies

2 other study(ies) available for peptide elongation factor 2 and nelfinavir

ArticleYear
Pharmacological eEF2K activation promotes cell death and inhibits cancer progression.
    EMBO reports, 2016, Volume: 17, Issue:10

    Topics: AMP-Activated Protein Kinases; Animals; Cell Death; Cell Line; Cell Survival; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance; Elongation Factor 2 Kinase; Female; Gene Expression; Humans; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Knockout; Multiprotein Complexes; Nelfinavir; Neoplasms; Peptide Elongation Factor 2; Phosphorylation; Protein Biosynthesis; TOR Serine-Threonine Kinases; Tumor Burden

2016
Functionally distinct roles for eEF2K in the control of ribosome availability and p-body abundance.
    Nature communications, 2021, 11-23, Volume: 12, Issue:1

    Topics: Animals; Cell Line, Tumor; Cryoelectron Microscopy; Elongation Factor 2 Kinase; Ganglia, Spinal; Humans; Male; Mice; Mice, Knockout; Nelfinavir; Peptide Elongation Factor 2; Phosphorylation; Primary Cell Culture; Processing Bodies; Protein Biosynthesis; Ribosomes; Sensory Receptor Cells

2021